Drug Profile
ADX 71149
Alternative Names: ADX-71149; JNJ-1813; JNJ-40411813; JNJ-mGluR2-PAMLatest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Addex Pharmaceuticals
- Developer Addex Therapeutics; Janssen Research & Development; Johnson & Johnson Innovative Medicine
- Class Antidepressants; Antiepileptic drugs; Antipsychotics; Anxiolytics; Piperidines; Pyridines; Small molecules
- Mechanism of Action Metabotropic glutamate receptor 2 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Epilepsy; Seizures
- No development reported Panic disorder
- Discontinued Major depressive disorder; Psychiatric disorders; Schizophrenia
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Epilepsy(In volunteers) in Japan (PO)
- 28 Feb 2024 No recent reports of development identified for preclinical development in Panic-disorder in Switzerland (PO)
- 08 Feb 2024 Addex Therapeutics completes a phase-II trial for Seizures (Adjunctive treatment, In adults, In the elderly) in Belgium, Germany, Poland, Russia, South Korea, Spain, Ukraine and USA (NCT04836559)